CAMP4 Therapeutics receives UK authorization for Phase 1/2 CMP-002 trial
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and ArgentinaCompany anticipates initiation of the clinical trial in 4Q 2026WATERTOWN, Mass., Sept. 10, 2026 (GLOBE…